Search

Anavex Life Sciences Corp

Abrir

SetorSaúde

3.08 -3.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.16

Máximo

3.29

Indicadores-chave

By Trading Economics

Rendimento

4.1M

-5.7M

EPS

0.08

Funcionários

34

EBITDA

-821K

-6.5M

Dividendos

By Acuity

Próximos Ganhos

24 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

57M

288M

Abertura anterior

6.53

Fecho anterior

3.08

Sentimento de Notícias

By Acuity

73%

27%

312 / 340 Ranking em Healthcare

Anavex Life Sciences Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de ago. de 2026, 23:41 UTC

Anavex Life Sciences Corp shares are higher during after-market hours, supported by a broader market trend. No specific company news was identified.

25 de ago. de 2026, 20:07 UTC

Event
News

Anavex Life Sciences reported Q3 2026 net income of $7.8 million, returning to profitability. Shares are trading higher following the financial results and pipeline updates.

24 de ago. de 2026, 23:11 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, building on positive momentum from Monday's close and a strong one-month performance.

21 de ago. de 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 de ago. de 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 de ago. de 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 de ago. de 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 de ago. de 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

13 de ago. de 2026, 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

12 de ago. de 2026, 19:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Tuesday's close, despite remaining above the 20-day moving average.

11 de ago. de 2026, 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

10 de ago. de 2026, 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

7 de ago. de 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 de ago. de 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 de ago. de 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 de ago. de 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 de ago. de 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 de jul. de 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 de jul. de 2026, 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 de jul. de 2026, 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 de jul. de 2026, 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 de jul. de 2026, 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 de jul. de 2026, 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Comparação entre Pares

Variação de preço

Anavex Life Sciences Corp Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

312 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat